Please assess the completion status of the following clinical trial:

Trial Title: Inpatient Clinical Trial of NAC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female between the ages of 18 and 80 years of age at Visit 1~2. Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.~3. Able to perform reproducible spirometry according to ATS criteria~4. Physiological evidence of airflow obstruction (FEV1 bronchodilator reversibility of ≥ 12% or hyperreactivity to methacholine reflected by a methacholine PC20 ≤ 16 mg/mL)~5. Clinical history of asthma per patient report or medical record~6. Pre-bronchodilator FEV1 \> 35% predicted~7. Post-bronchodilator FEV1 \> 40% but \< 90% predicted~8. Asthma requiring treatment with inhaled corticosteroids (ICS) for 3 months or greater~9. CT mucus score \> 3~Exclusion Criteria:~1. Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study.~2. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.~3. Smoking of tobacco or other recreational inhalants in last year and/or \>10 pack-year smoking history~4. Current participation in an investigational drug trial~5. Other chronic pulmonary disorders, including (but not limited to) cystic fibrosis, chronic obstructive pulmonary disease, chronic bronchitis, vocal cord dysfunction (that is the sole cause of respiratory symptoms and at the PI's discretion), severe scoliosis or chest wall deformities that affect lung function, or congenital disorders of the lungs or airways~6. Unwillingness to follow study procedures~7. History of allergy or intolerance to study drug~8. Any other criteria that places the subject at unnecessary risk according to the judgment of the Principal Investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- N-acetylcysteine (Type: EXPERIMENTAL): This study will look at the effects of a medication, called n-acetylcysteine or NAC, on lung function. NAC is already approved for use in people with chronic airway conditions, including asthma. However, it is not known who this medication works best in. We believe this medication will likely have the most benefit in people with asthma that have mucus in their airways or mucus plugging. Initial study procedures will include lung function measurements, a low dose CT scan, a blood draw, and a sputum induction. The CT lung imaging will identify asthmatics with mucus plugs.

Based on this trial design, predict the completion outcome and termination type (if applicable).